Invest in U-Pump

Hi, I’m Alexander, CEO of U-Pump.

Diabetes isn’t just a condition—it’s a constant battle.

Millions struggle with insulin therapy because current solutions are outdated, inconvenient, or simply unaffordable.

We believe diabetes management should be easy and accessible for everyone.

That’s why we built U-Pump — the first AI-powered, reusable patch pump that makes insulin therapy effortless, affordable, and available to millions.

500+ million people worldwide have diabetes, and that number is rising.

Insulin therapy costs between $5,000 and $12,000 per year, but only 20% of insulin-dependent patients use pumps.

Why? Because existing pumps are either bulky and restrictive or disposable and expensive — leaving millions with outdated, manual insulin injections.

Big players haven’t solved this.

It’s time for something better..

U-Pump removes the key barriers stopping people from using pumps.

As comfortable as a patch pump,  as affordable as a reusable pump.

• OneMove™ Technology makes installation effortless—no tubes, no hassle.
• Eco-friendly, replaceable cartridges, cutting costs and medical waste.
• Transparent subscription model—no middlemen, no hidden fees.

We’re making insulin therapy accessible to millions who have been left behind.

U-Pump is fully integrated with CGMs like Dexcom and Libre for real-time glucose tracking.

• AI-powered dosing adjusts insulin delivery in real-time, reducing hypoglycemia risk.
• Swiss-level precision in a compact, tubeless design that seamlessly fits into daily life.

We are ready for mass production to make advanced insulin therapy affordable worldwide.

And the demand is real—400+ pre-orders and growing.

The global insulin pump market is projected to hit $13B by 2029, driven by the demand for smarter, more accessible therapy.

Yet in the U.S., 4 million insulin users remain underserved—not because they don’t need pumps, but because they can’t afford them.

U-Pump changes that—our pricing and insurance coverage make it accessible to twice as many users.

By integrating with Medicare, private insurers, pharmacies (CVS, Walgreens), and diabetes organizations (ADA, JDRF), we ensure rapid adoption and scalable growth.

We unlock a multi-billion-dollar market with 15M+ potential users worldwide.

We’ve worked full-time for 18 months to bring U-Pump to life.

We’ve completed our MVP and metrological testing.

We are actively preparing for pre-FDA submission (typically a 90-day process).

We were already in talks with Dexcom Ventures, exploring strategic partnerships and investments.

We start in Israel and the U.S., then expand worldwide.

Phase 1: Direct online sales for rapid early adoption.

Phase 2: Scale through insurance partnerships (Medicare, private insurers), pharmacy chains (CVS, Walgreens), and doctor recommendations.

Reimbursement approvals with Medicare Part B/D and private insurers will drive accessibility, while partnerships with JDRF, ADA, and endocrinologists will build trust.

• Customer acquisition cost: $1,500.
• Customer lifetime value: $8,700.

Our target: Insulin-dependent individuals (ages 18–65) who want:

• Affordable, hassle-free diabetes management.
• Seamless integration with CGMs and health tech.
• AI-driven, reliable, and user-friendly solutions.
• A smarter insulin pump.

Unlike competitors with high upfront costs, U-Pump combines hardware sales, subscriptions, and insurance coverage for affordability and profitability.

Customer acquisition cost: $1,500. Customer lifetime value: $8,700.

• LTV/CAC ratio of 5.6—a winning formula for sustainable growth.
• 80–90% margins across revenue streams.
• Each customer generates $10,000+ in revenue over 4 years.
• Projected revenue: $127M by first Year, $1.4B by Year 4.

Our FDA roadmap is clear — backed by Hogan Lovells’ and our Advisors regulatory expertise and pilot programs with leading diabetes research centers in Bern and Boston.

We are obtaining FDA 510(k) clearance by proving our device is similar to existing approved products, which speeds up the approval process.

This typically takes 1-3 years, and we plan to open pre-orders during this period.

• 435 pre-orders.
• 2 patents filed, 4 more in progress.
• Parallel reimbursement approvals codes (HCPCS, CPT) for a seamless launch.
• Strategic distribution talks with CVS, Walgreens, and private insurers.

We compete with Medtronic, Tandem, and Insulet, but here’s why U-Pump stands out:

• No tubes, no hassle—just seamless insulin delivery.
• Minimum 20% cheaper than traditional pumps, that cuts annual diabetes management costs by up to $1,000 per patient per year.
• Subscription model removes financial barriers.
• Integrated with insurance for broader accessibility.

We’re not just another pump—we’re expanding the market and reaching those left behind.

Our team with deep expertise in healthcare, tech, and business:

• Alexander Senkevich (CEO) – 15+ years in life sciences, founder of QRepublik Medical ID, graduate of York Entrepreneurship Development Institute & University of Strasbourg.
• Mikhail Zeppelin (CTO) – 15+ years in device development, including 7 years in medical and insulin systems.
• Klim Todrik (IT Lead) – 10+ years in AI-driven, user-friendly health tech solutions.

Our Adviser:

• Dr. Elena Omelchenko – Diabetologist at Maccabi Health Services.
• Mikhail Pliss – Regulatory & technology expert with FDA & CE compliance experience.

With 6 specialists and regulatory and IP experts, we are ready to make U-Pump the future of insulin therapy.

We are raising $5M in pre-seed funding via SAFE agreements (starting from $200K).

Funds will be used to:

✅ Finalize product development.

✅ Submit pre-FDA clearance.

✅ Accelerate market launch.

Investment Strategy:

Investment Instruments: SAFE. The $15M valuation is based on similar deals on Crunchbase/Dealroom.

U-Pump isn’t just another insulin pump—it’s a breakthrough in diabetes care. It’s:

✅ Affordable.

✅ Effortless.

✅ Scalable.

We remove barriers to insulin therapy, making it accessible to millions who need it most.

Join us in revolutionizing diabetes care.